BerandaMOR • ETR
add
MorphoSys AG
Tutup sebelumnya
€67,65
Rentang hari
€67,65 - €68,00
Rentang tahun
€14,52 - €69,75
Kapitalisasi pasar
2,55 M EUR
Volume Rata-Rata
66,52 rb
Rasio P/E
-
Hasil dividen
-
Bursa utama
ETR
Dalam berita
Keuangan
Laporan Pendapatan
Pendapatan
Laba bersih
| (EUR) | Mar 2024info | Perubahan Y/Y |
|---|---|---|
Pendapatan | 27,54 jt | 13,11% |
Biaya operasional | 289,14 jt | 264,02% |
Laba bersih | -314,96 jt | -608,87% |
Margin laba bersih | -1,14 rb | -526,67% |
Penghasilan per saham | -8,27 | -529,19% |
EBITDA | -263,38 jt | -388,32% |
Tarif pajak efektif | 0,51% | — |
Neraca
Total aset
Total liabilitas
| (EUR) | Mar 2024info | Perubahan Y/Y |
|---|---|---|
Investasi tunai jangka pdk | 630,77 jt | -20,30% |
Total aset | 1,83 M | -17,85% |
Total liabilitas | 2,09 M | -1,84% |
Total ekuitas | -261,67 jt | — |
Saham yang beredar | 37,62 jt | — |
Harga terhadap reservasi | -9,72 | — |
Tingkat pengembalian aset | -34,27% | — |
Pengembalian modal | -41,11% | — |
Arus Kas
Perubahan bersih tunai
| (EUR) | Mar 2024info | Perubahan Y/Y |
|---|---|---|
Laba bersih | -314,96 jt | -608,87% |
Kas dari operasi | -71,53 jt | 14,27% |
Tunai dari investasi | 28,62 jt | 187,62% |
Tunai dari pembiayaan | -950,28 rb | 97,86% |
Perubahan bersih tunai | -27,24 jt | 75,37% |
Arus kas bebas | 246,91 jt | 1.523,66% |
Tentang
MorphoSys AG is a German biopharmaceutical company founded in 1992. The company is headquartered near Munich, Germany, and has a wholly owned subsidiary, MorphoSys US Inc., in Boston, Massachusetts, in the US. The company has various antibody, protein and peptide technologies that it uses to discover and develop both proprietary and partnered drug candidates. The company has more than 100 drugs in its wider pipeline that are being investigated for a variety of diseases. While many of these are being developed in partnership with pharma and biotech companies, MorphoSys also has a proprietary pipeline with a focus on cancer and autoimmune diseases.
MorphoSys AG is listed on the Frankfurt Stock Exchange and on the US Nasdaq stock exchange. Novartis agreed to acquire the company in February 2024. Wikipedia
Didirikan
1992
Kantor pusat
Situs
Karyawan
464
